These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38821604)
21. The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. Lv C; Zeng HW; Wang JX; Yuan X; Zhang C; Fang T; Yang PM; Wu T; Zhou YD; Nagle DG; Zhang WD Cell Death Dis; 2018 Feb; 9(2):165. PubMed ID: 29416003 [TBL] [Abstract][Full Text] [Related]
22. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer. Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865 [TBL] [Abstract][Full Text] [Related]
23. Targeting PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis. Redlak MJ; Miller TA Dig Dis Sci; 2011 Feb; 56(2):323-9. PubMed ID: 20585984 [TBL] [Abstract][Full Text] [Related]
24. EPHA2 Promotes the Invasion and Migration of Human Tongue Squamous Cell Carcinoma Cal-27 Cells by Enhancing AKT/mTOR Signaling Pathway. Wang F; Zhang H; Cheng Z Biomed Res Int; 2021; 2021():4219690. PubMed ID: 33834064 [TBL] [Abstract][Full Text] [Related]
25. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells. Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586 [TBL] [Abstract][Full Text] [Related]
26. Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide. Horibe T; Torisawa A; Kohno M; Kawakami K BMC Cancer; 2014 Aug; 14():615. PubMed ID: 25159299 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. Chen G; Chen SM; Wang X; Ding XF; Ding J; Meng LH J Biol Chem; 2012 Apr; 287(15):12132-41. PubMed ID: 22337890 [TBL] [Abstract][Full Text] [Related]
29. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells. Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406 [TBL] [Abstract][Full Text] [Related]
30. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway. Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494 [TBL] [Abstract][Full Text] [Related]
31. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway. Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505 [TBL] [Abstract][Full Text] [Related]
33. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model. Nam S; Kim H; Hong D; Park JB; Kim SJ Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812 [TBL] [Abstract][Full Text] [Related]
34. Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway. Wang N; Feng T; Liu X; Liu Q Acta Pharm; 2020 Sep; 70(3):399-409. PubMed ID: 32074070 [TBL] [Abstract][Full Text] [Related]
35. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway. Zheng J; Liu C; Shi J; Wen K; Wang X Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077 [TBL] [Abstract][Full Text] [Related]
36. The effects of Hsp90 expression alteration on spinal metastases of breast carcinoma. Yan W; Xiao J; Liu T; Huang W; Yang X; Wu Z; Huang Q; Qian M Tumour Biol; 2013 Jun; 34(3):1391-7. PubMed ID: 23456764 [TBL] [Abstract][Full Text] [Related]
37. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Smith JR; Clarke PA; de Billy E; Workman P Oncogene; 2009 Jan; 28(2):157-69. PubMed ID: 18931700 [TBL] [Abstract][Full Text] [Related]
38. Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells. Jeong YJ; Choi Y; Shin JM; Cho HJ; Kang JH; Park KK; Choe JY; Bae YS; Han SM; Kim CH; Chang HW; Chang YC Food Chem Toxicol; 2014 Jun; 68():218-25. PubMed ID: 24675423 [TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049 [TBL] [Abstract][Full Text] [Related]
40. Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Du L; Li X; Zhen L; Chen W; Mu L; Zhang Y; Song A Mol Med Rep; 2018 May; 17(5):7163-7169. PubMed ID: 29568883 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]